Use of Serologic Responses against Enteropathogens to Assess the Impact of a Point-of-Use Water Filter: A Randomized Controlled Trial in Western Province, Rwanda

Laura Divens Zambrano,^{1*} Jeffrey W. Priest,² Emil Ivan,³ John Rusine,³ Corey Nagel,⁴ Miles Kirby,⁵ Ghislaine Rosa,⁵ and Thomas F. Clasen^{1,5}

¹Department of Environmental Health, Emory University Rollins School of Public Health, Atlanta, Georgia; ²Division of Foodborne, Waterborne and Environmental Diseases, National Center for Zoonotic and Emerging Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; ³National Reference Laboratory, Rwanda Biomedical Center, Kigali, Rwanda; ⁴OHSU/PSU School of Public Health, Oregon Health and Science University, Portland, Oregon; ⁵Department of Disease Control, London School of Hygiene and Tropical Medicine, London, United Kingdom

Abstract. Diarrhea is a leading contributor to childhood morbidity and mortality in sub-Saharan Africa. Given the challenge of blinding most water, sanitation, and hygiene (WASH) interventions, diarrheal disease outcome measures in WASH intervention trials are subject to potential bias and misclassification. Using the platform of a cluster-randomized controlled trial of a household-based drinking water filter in western province, Rwanda, we assessed the impact of the drinking water filter on enteric seroconversion in young children as a health outcome and examined the association between serologic responses and caregiver-reported diarrhea. Among the 2,179 children enrolled in the trial, 189 children 6–12 months of age were enrolled in a nested serology study. These children had their blood drawn at baseline and 6–12 months after the intervention was distributed. Multiplex serologic assays for *Giardia*, *Cryptosporidium*, *Entamoeba histolytica*, norovirus, *Campylobacter*, enterotoxigenic *Escherichia coli* and *Vibrio cholerae* were performed. Despite imperfect uptake, receipt of the water filter was associated with a significant decrease in seroprevalence of IgG directed against *Cryptosporidium parvum* Cp17 and Cp23 (relative risk [RR]: 0.62, 95% confidence interval [CI]: 0.44–0.89). Serologic responses were positively associated with reported diarrhea in the previous 7 days for both *Giardia intestinalis* (RR: 1.94, 95% CI: 1.04–3.63) and *C. parvum* (RR: 2.21, 95% CI: 1.09–4.50). Serologic responses for all antigens generally increased in the follow-up round, rising sharply after 12 months of age. The water filter is associated with reduced serologic responses against *C. parvum*, a proxy for exposure and infection; therefore, serologic responses against protozoa may be a suitable health outcome measure for WASH trials among children with diarrhea.

INTRODUCTION

Diarrheal disease is the fourth leading contributor to global child mortality,^{1,2} due principally to unsafe water, poor sanitation, and hygiene.³ Young children aged 0–24 months are particularly vulnerable to severe diarrhea after initial exposure to specific pathogens, particularly after 6 months of age when maternally acquired humoral immunity wanes.⁴ Diarrhea is associated with malnutrition and growth faltering,^{5–7} and poor nutritional status resulting from diarrhea places young children at a higher risk of death. Diarrheal disease is a leading cause of morbidity and mortality in Rwanda,^{1,2} and environmental and demographic factors contribute to both diarrhea and stunting in the country.⁸

Household water treatment (HWT) appears to be effective in reducing diarrheal disease among populations with unsafe sources of drinking water.⁹ Evidence of its effectiveness, however, is derived from nonblinded trials that report diarrheal disease as an outcome. Reported outcomes of water, sanitation, and hygiene (WASH) intervention trials, such as self-reported diarrheal disease, are subject to both recall and courtesy biases; such trials are highly subjective and unable to distinguish specific causal pathogens of the disease.¹⁰ Objective measures of exposures are particularly important in trials of environmental health interventions that cannot be blinded.¹¹

Objective outcome measures were incorporated in a recent meta-analysis of 54 studies examining the impact of WASH on

intestinal protozoa infection, which found that the general availability and use of WASH interventions was associated with significantly lower odds of *Entamoeba histolytica*, *Giardia intestinalis*, and *Cryptosporidium* spp. infections. Diagnostics were typically performed with stool examination.¹² Although stool assays offer an opportunity for more objective assessment, logistical constraints related to the storage, transport, and extensive laboratory work involved can limit their utility in resource-limited settings.¹³ In addition, the ability of stool assays to detect etiologic agents can be limited, as in the case of some protozoa, when cysts or oocysts are not continuously shed.¹⁴ Disease prevalence can also vary widely by season,¹⁵ so IgG/IgG4 assays can provide additional means of ascertaining exposure retrospectively throughout the study period as opposed to using stool cultures, which may only detect pathogens that are present at the time of collection.

Quantitative assays that detect serologic IgG antibody responses against various enteropathogens can provide a useful measure of prior exposures to enteropathogens in children and may supplement relatively subjective caregiver-reported diarrheal disease outcomes.¹⁶ Antibody responses that recognize some enteric pathogen antigens are transiently expressed, allowing researchers to infer some degree of temporality with regard to the timing of exposures, positive stools and, in some cases, the number of recent infections.^{17,18} For protozoan infections, cyst-positive stools appear to co-occur with serologic responses to *E. histolytica* and *Giardia intestinalis*, with higher seroprevalence in children for whom stool samples were collected within 1 week of serum collection versus 2 weeks or more,¹⁹ indicating that serologic responses can be an indicator of recent protozoan infections. Antibody responses in cryptosporidiosis patients are

* Address correspondence to Laura Divens Zambrano, Department of Environmental Health, Emory University Rollins School of Public Health, 1518 Clifton Road NE, Atlanta, GA 30329. E-mail: laura.zambrano@alumni.emory.edu

consistently directed against 23- and 17-kDa *Cryptosporidium parvum* antigens (Cp23 and Cp17, respectively) and are known to have a 12-week half-life in adults.¹⁷ Immunoassays also provide the opportunity to characterize age-specific cumulative exposures to enteropathogens that can enhance epidemiological surveillance and inform etiology-specific interventions and regionally specific treatment strategies.²⁰ Children under 24 months of age are the ideal population to examine seroconversion as maternally derived antibodies typically have waned¹³ and initial exposure to enteropathogens often occurs within the first 2 years of life.

Microsphere-based multiplex immunoassay methods allow for simultaneous measurement of antibodies against multiple antigens. Previously, this technology has been applied to neglected tropical disease surveillance, particularly those diseases targeted for global elimination.²¹ In recent years, single enzyme-linked immunosorbent assays and multiplex immunoassays have been shown to effectively target antigens of various enteropathogens,^{13,16–19,22,23} but the technique's incorporation into intervention trials has not been adequately explored. One trial¹⁶ and a few cross-sectional or longitudinal population studies^{13,18,19,23,24} have incorporated this approach in the past, but have not included the full range of enteric antigens that are now currently available.

We undertook this study in the context of a large-scale cluster-randomized controlled trial (CRT) described elsewhere.²⁵ We aimed to assess the effectiveness of a point-of-use water filter on seroconversion against a panel of viral, bacterial, and protozoan enteropathogens among young children. We also sought to explore the potential for using serologic response as an objective alternative to reported diarrhea to assess the effectiveness of water quality interventions, an approach that has been advocated in other serologic studies.^{16,18}

METHODS

Intervention. In an effort to reduce the high prevalence of waterborne disease in western province, Rwanda, DelAgua Health, Inc. (DelAgua, Wiltshire, United Kingdom) distributed point-of-use water filters to the poorest 30% (*Ubudehe* 1 and 2) of households. The Vestergaard Frandsen (Lausanne, Switzerland) LifeStraw™ Family 2.1 filter employs a 0.2- μ m hollow-fiber ultrafiltration membrane designed to remove bacteria, parasites, and select viruses from source water. This system can filter up to 18,000 L of water, supplying a family of five with clean drinking water for 3–5 years.²⁶ This system exceeds the World Health Organization's "highly protective" standard for household water treatment technologies.²⁷ Participating households also received an improved biomass cook stove.

Study design. We assessed the effectiveness of the intervention by conducting a CRT in Western Province, Rwanda, using diarrhea in the previous 7 days as our primary outcome. The study design for the CRT has been described elsewhere²⁵ and was informed by previously described pilot studies^{28,29} and government-reported disease prevalence data.³⁰ The intervention was delivered to all eligible households among 72 randomly selected sectors, with the remaining 24 sectors serving as controls. Outcomes for the sector-level study will be drawn from clinical records collected from all health clinics and community health workers in the study area. To assess coverage and use of the intervention, and to measure its

impact on drinking water quality and other outcomes unavailable from health clinic records, we conducted a village-level study that consisted of intensive longitudinal data collection among households in 174 randomly selected villages divided equally among intervention and control sectors. For this nested village-level study, we sought to enroll up to 10 households with at least one child under 4 years old per village. We ultimately enrolled 1,582 total households with 2,179 children. Following a baseline conducted from late August through early December 2014, we conducted three follow-up rounds in the same households from February 2015 through March 2016.

Enteric serologic study. For this seroconversion substudy, we assessed serologic responses against a panel of 12 antigens representing nine of the most common causes of diarrhea in this region,³¹ relative to age and intervention status. Our enumerators were instructed to enroll all 6- to 12-month-old children residing in the households selected for intensive data collection during the baseline round of the CRT. These children had one blood sample drawn at baseline and a second sample 12 months later during follow-up. We conservatively estimated that 40% of children would seroconvert from negative to positive for *C. parvum* and norovirus antibody between baseline and follow-up in the absence of any intervention, based on a previous trial in Guatemala.¹⁶ If 87 children from each of our two study arms were enrolled in the study, we would have 80% power at $\alpha = 0.05$ to detect a difference in seroconversion against any antigen of 40% versus 22.5% in our intervention and control groups.

Between 3 and 6 small hanging drops of blood (10 μ L each for a total of 30–60 μ L) were collected on TropBio™ filter discs (Cellabs Pty Ltd., Brookvale, New South Wales, Australia) and kept in individual plastic resealable containers during the fieldwork. Immediately on return to the field office each day, the discs were placed on a table and allowed to dry overnight. The following morning, they were individually packaged in plastic resealable bags with desiccant, and were sent within 7 days of collection to the Rwanda National Reference Laboratory in Kigali, Rwanda, for long-term storage at -20°C .

Laboratory methods. All laboratory analyses were performed at the Centers for Disease Control and Prevention (CDC) Infectious Disease Laboratories in Atlanta, GA. Total IgG responses against relevant enteropathogens were quantified using a multiplex SeroMAP™ microsphere-based immunoassay on the Luminex xMAP platform (Luminex Corp, Austin, TX). Antigens used in this assay were *Schistosoma japonicum* glutathione-S-transferase (GST) protein control²⁴; *Toxoplasma gondii* surface antigen 2A gene/GST fusion (SAG2A)³²; *G. intestinalis* variant-specific surface protein AS8/GST fusion (VSP3)^{23,33} and variant-specific surface protein 42e/GST fusion (VSP5)^{23,34}; virus-like particles (VLPs) for three norovirus strains (Norwalk, Sydney and St. Cloud) kindly provided by Jan Vinje and Veronica Costantini (CDC); *Campylobacter jejuni* p39 antigen and *Campylobacter* p18 antigen³⁵; Enterotoxigenic *Escherichia coli* (ETEC) heat-labile toxin β subunit (EtxB) (Sigma Chemical Co., St. Louis, MO); *C. parvum* 17-kDa protein/GST fusion (Cp17) and *C. parvum* 23-kDa protein/GST fusion (Cp23)²³; cholera toxin β subunit (CtxB) (Sigma); and *E. histolytica* Gal/GalNAc lectin heavy chain subunit (LecA) (kindly provided by W. Petri, Univ. of Virginia School of Medicine).^{19,36}

The *C. jejuni* antigens were expressed as GST fusion proteins in pGEX-4T2 vector (GE Healthcare, Piscataway, NJ) using the same polymerase chain reaction (PCR) and directional cloning strategies as previously described for the *T. gondii* SAG2A protein.³⁷ The forward and reverse deoxy-oligonucleotides used in the PCR reactions were: 5'-CGC GGA TCC GTT ATT AGT GGT TGT AGC AC-3' and 5'-GCG GAA TTC TTA TCT TGA TAA TTT AAA TTC-3', respectively, for p18; and 5'-CGC GGA TCC CCT GTA AGA TTT AGT TTA AAT C-3' and 5'-GCG GAA TTC TTA GTT TAA AGT ATA AAG CTT G-3', respectively, for p39. Proteins were expressed in *E. coli* Hb101 cells (Promega Corp., Madison, WI), purified on a glutathione Sepharose 4B affinity column (GE Healthcare) as directed by the manufacturer, and additionally purified by Mono Q chromatography (HR 5/5 column; GE Healthcare) using a 20-minute linear elution gradient of 0–0.6 M NaCl in 25 mM Tris (pH 7.5) at a flow rate of 1 mL/min. The proteins eluted at approximately 0.25 M NaCl on the gradient profile. Protein yield (BCA microassay; Pierce Chemical, Rockford, IL) was > 3 mg/L of culture.

Bead coupling. Procedures describing the coupling process of antigens to microspheres have been described in detail elsewhere.^{23,24} The carboxyl groups on each bead were esterified and then reacted with the primary amine groups of each antigen to bind the antigens to the microspheres through a covalent amide bond. Norovirus VLP antigens were coupled in buffer containing 10 mM Na₂HPO₄ and 0.85% NaCl at pH 7.2 (phosphate-buffered saline [PBS]) using 30 µg protein/12.5 × 10⁶ beads. All other antigens used in this study were coupled in buffer containing 25 mM 2-(*N*-morpholino)-ethanesulfonic acid and 0.85% NaCl at pH 5.0. The amounts of protein coupled to 12.5 × 10⁶ beads were GST control, 15 µg; *T. gondii* SAG2A, 12.5 µg; *G. intestinalis* VSP3 and VSP5, ETEC and cholera toxin β subunits, and *E. histolytica* LecA, 30 µg; *C. parvum* Cp17, 6.8 µg; *C. parvum* Cp23, 12.5 µg; *C. jejuni* p18 and p39, 25 µg. Beads were quantified by a hemocytometer and stored at 4°C in PBS with 1.0% bovine serum albumin, 0.05% Tween 20 and 0.02% sodium azide (NaN₃) and the following protease inhibitors: 200 µg of pepabloc (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride) (Roche Diagnostics, Indianapolis, IN), 200 µg ethylenediaminetetraacetic acid, and 1 µg of both leupeptin and pepstatin A.¹⁹

Serum preparation. The elution process loosely followed a protocol described elsewhere for antibody elution from the TropBio dried blood spots (DBSs).³⁸ Elution buffer was made with 0.05% Tween-20 and 0.05% NaN₃ in PBS. DBS tabs were removed from –20°C, brought to room temperature, and submerged in 200 µL of elution buffer for a minimum of 18 hours at 4°C. DBS tabs were considered acceptable for use if > 90% of the filter paper was red (indicative of saturation with 10 µL of whole blood). Eluted serum (50 µL) was diluted into 450 µL of dilution buffer for a final serum dilution of 1:400 (assuming a hematocrit of 50%). Dilution buffer consisted of PBS with 0.50% polyvinyl alcohol (PVA), 0.80% polyvinylpyrrolidone (PVP), 0.50% casein, 0.30% Tween-20, and 0.02% NaN₃, and *E. coli* extract at a final protein concentration of 3 µg/mL. PVA and PVP were added to reduce background while not affecting specificity.¹⁹

Multiplex bead assay. Multiplex assay conditions have previously been described.^{18,19} All samples were run in duplicate. Controls run on each 96-well plate included a buffer-only

blank, one negative control, and five positive controls. The background from the buffer-only blank was subtracted from the result for each antigen, and values are reported as an average median fluorescent intensity with background subtracted (MFI-bg). A % coefficient of variation (%CV) was calculated from the duplicate well values, and samples were repeated if the %CV values for three or more positive responses exceeded 15% (*N* = 8).

Cutoff determination. Cutoff values were previously established for *C. parvum* Cp17 and 23 using an receiver operating characteristic curve based on Western blot data²² and for *G. intestinalis* using the mean MFI-bg values plus three standard deviations of serum drawn from a panel of U.S. adults with no history of foreign travel. For the remaining antigens, cutoffs were determined through finite mixture models of two Gaussian distributions of continuous MFI values.^{20,39} Procedures for establishing cutoff values for seropositivity are described in further detail in the Supplemental Material.

Multiple imputation. To account for sample loss at baseline and follow-up, multiple imputation methods using fully conditional specification⁴⁰ were used to impute missing values using predictors of diarrhea at baseline. These predictors were incorporated as potential covariates in individual models predicting MFI values for each antigen and were retained in imputation models if they were associated with antibody response at $\alpha = 0.35$. This process generated 25 imputed datasets. Multiple imputation procedures are described in further detail in the Supplemental Methods.

Statistical analysis. To assess the impact of the intervention on serologic responses against the enteropathogen antigens explored in this study, we first performed a comparison for the continuous measures for antibody response (MFI) between intervention arms. For all antibodies assessed in this study, the serologic responses as measured by MFI were not normally distributed. Goodness-of-fit tests were performed on all log-transformed values against a normal distribution to examine the appropriateness of applying a continuous MFI outcome variable for parametric analyses. If log-transformed continuous variables fit a normal distribution, they were subject to linear regression. The change in log-transformed MFI between baseline and follow-up (Δ MFI-bg) was compared between intervention and control groups using a *t* test with a pooled variance estimator where parametric analyses were possible. All variables that could not be transformed to fit a common statistical distribution were only analyzed for serologic response relative to their cutoff values.

Seroconversion and prevalence of serologic responses against enteropathogens in this study were calculated using both available and imputed data. MFI-bg data for each antigen were dichotomized above and below their respective cutoff points at baseline and follow-up. Binary seroprevalence estimates were calculated among children in households randomized to intervention households and compared with children in control households using log binomial models on both observed and imputed data.⁴¹ Village-level clustering was accounted for through robust variance estimation; for imputed data, generalized estimating equation (GEE) parameter estimates with empirical standard errors were calculated and combined to generate valid statistical inferences of the associations under study.⁴² For seroconversion analyses, a child was considered to have seroconverted against a particular antigen if their MFI-bg values were below the cutoff at

TABLE 1
Child and household characteristics among children enrolled in this serologic substudy, disaggregated by study arm

Characteristics	Intervention (N = 75) count (%)	Control (N = 114) count (%)	Total (N = 189) count (%)
Female	40 (53.3)	54 (47.4)	94 (49.7)
Age at enrollment (months)			
6	1 (1.5)	1 (1.0)	2 (1.2)
7–8	22 (32.4)	36 (35.6)	58 (34.3)
9–10	18 (26.5)	38 (37.6)	56 (33.1)
11–12	27 (39.7)	26 (25.7)	53 (31.4)
Socioeconomic status*			
Lowest	10 (13.3)	18 (15.8)	28 (14.8)
Second lowest	11 (14.5)	20 (17.5)	31 (16.4)
Middle	14 (18.7)	26 (22.8)	40 (21.2)
Second highest	21 (28.0)	27 (23.7)	48 (25.4)
Highest	19 (25.3)	23 (20.2)	42 (22.2)
Time between rounds (months)			
6–7	1 (1.5)	0	1 (0.6)
8–9	31 (46.3)	69 (67.0)	100 (58.8)
10–12	35 (52.2)	34 (33.0)	69 (40.6)
Primary water source			
Piped water into dwelling or plot	1 (1.3)	0	1 (0.5)
Hand pump/borehole	18 (24.0)	30 (26.6)	48 (25.5)
Protected spring/well	40 (53.3)	54 (47.8)	94 (50.0)
Unprotected spring/well	13 (17.3)	20 (17.7)	33 (17.6)
Surface water	3 (4.0)	9 (8.0)	12 (6.4)
Toilet type			
Pit latrine with slab	24 (33.8)	35 (34.0)	59 (33.9)
Pit latrine with no slab	45 (63.4)	60 (58.3)	105 (60.3)
Ventilated pit latrine	0	3 (2.9)	3 (1.7)
Composting toilet	2 (2.8)	5 (4.9)	7 (4.0)
Feces within 1 M of toilet	31 (41.3)	41 (36.0)	72 (38.1)
Shared sanitation	24 (32.0)	27 (24.6)	51 (27.8)

* Socioeconomic status quintile determined through polychoric principal components analysis, as described in the supplement.

baseline but above the cutoff at follow-up. Seroconversion prevalence was compared with both observed and imputed data between intervention and control groups using log binomial models with robust variance estimation to account for intra-village clustering to calculate the relative risk of

seroconversion at follow-up against any specific antigen among children in the intervention versus control arm. Models were selected using backward selection procedures in which the full model included age, gender, socioeconomic status, time between rounds, water source type, toilet type, toilet area

FIGURE 1. Sample flow from the enrollment to analysis stages for all children enrolled in the baseline and follow-up rounds of this study. Children were only eligible for blood draw during follow-up if they were initially enrolled during the baseline round.

TABLE 2

Comparison of median MFI values with background subtracted (MFI-bg) at follow-up (N = 152), and the change in MFI-bg (Δ MFI-bg) from baseline to follow-up (N = 97) compared between children in intervention (LifeStraw) and control households with a paired t test

Antigen*	Intervention (N = 62)			Control (N = 91)			Intervention (N = 34)			Control (N = 63)		
	Median (Q1,Q3) follow-up MFI-bg†	Median (Q1,Q3) follow-up MFI-bg†	t (P value)	Median (Q1,Q3) follow-up MFI-bg†	Median (Q1,Q3) follow-up MFI-bg†	t (P value)	Median (Q1,Q3) Δ MFI-bg†	Median (Q1,Q3) Δ MFI-bg†	β	t (P value)	β	t (P value)
<i>Cryptosporidium parvum</i>												
CpP2 (100)	11 (7,15)	10 (7,15)	0.50 (0.617)	1,043 (35,3303)	1,043 (35,3303)	-0.863	3 (-2,9)	3 (-3,6)	0.041	0.25 (0.800)	0.041	0.25 (0.800)
Cp17	438 (35,3303)	1,043 (35,3303)	-2.00 (0.047)	2,024 (167,8,404)	2,024 (167,8,404)	-0.542	371 (34,3,283)	763 (13,5,427)	-0.617	-0.97 (0.334)	-0.617	-0.97 (0.334)
Cp23	504 (69,4307)	2,024 (167,8,404)	-1.26 (0.209)				317 (34,3,484)	1,025 (24,7,666)	-0.160	-0.27 (0.786)	-0.160	-0.27 (0.786)
<i>Salmonella</i>												
LPS-B	10 (5,37)	5 (3,16)	1.59 (0.115)				7 (1,36)	2 (-2,13)	0.566	1.51 (0.136)	0.566	1.51 (0.136)
LPS-D	6 (4,12)	4 (3,8)	1.94 (0.055)				1.5 (0,11)	1 (-1,4)	0.556	1.82 (0.072)	0.556	1.82 (0.072)
Norovirus												
Norwalk	286 (36,4295)	270 (24,1,866)	0.49 (0.625)				37 (-35,1,168)	85 (-11,1,595)	-0.066	-0.10 (0.919)	-0.066	-0.10 (0.919)
Sydney	220 (43,903)	532 (128,1,374)	-1.18 (0.240)				122 (6,624)	375 (4,992)	-0.430	-0.93 (0.356)	-0.430	-0.93 (0.356)
St. Cloud	54.5 (17,136)	53 (19,207)	-0.31 (0.757)				42 (8,109)	38 (3,185)	-0.020	-0.05 (0.957)	-0.020	-0.05 (0.957)
<i>Toxoplasma gondii</i>												
SAG2	5 (3,8)	5 (3,8)	0.38 (0.703)				3 (0,7)	2 (-2,5)	0.320	1.23 (0.221)	0.320	1.23 (0.221)
<i>Campylobacter jejuni</i>												
p18	960.5 (174,5268)	1,073 (152,6,740)	0.22 (0.827)				858 (-1,5,806)	387 (-18,7,769)	0.559	0.99 (0.323)	0.559	0.99 (0.323)

ETEC = Enterotoxigenic *Escherichia coli*; MFI = median fluorescent intensity; VSP3 = variant-specific surface protein p39, and *Entamoeba histolytica* LecA. Refer to Tables 2 and 3 utilizing cutoff values for seropositivity.
 * Unable to transform MFI values for *Giardia* VSP3 and VSP5, ETEC EtxB, *Vibrio cholerae* CtxB, *Campylobacter* p39, and *Entamoeba histolytica* LecA. Refer to Tables 2 and 3 utilizing cutoff values for seropositivity.
 † Mean fluorescence intensity values can range from 1 to 32,766 without background subtracted, but MFI values with background values subtracted (Δ MFI-bg) can be negative.²²

cleanliness, and shared sanitation. Socioeconomic status was considered as a confounder and determined by an index calculated through a principal components analysis using polychoric correlations of discrete household asset variables,^{43,44} as described in further detail in the Supplemental Methods. Confounders were retained if they altered the effect size from the full model by more than 10%, and effect modifiers were considered if the magnitude or direction of the relationship between an exposure and the serologic outcome varied substantially by level of the modifier. Final models for each serologic outcome of interest are shown in Supplemental Table 5; we assessed confounding by other demographic, water, and sanitation factors when deemed appropriate by our model selection procedures, even though we found reasonable balance between study arms on most household and environmental factors collected at baseline (Table 1). Both unadjusted and adjusted log binomial models were run using observed and imputed data.

To assess the utility of serologic testing as an objective alternative to reported diarrhea, dichotomized MFI-bg values representing seroprevalence of antibody responses against each antigen were assessed relative to diarrhea prevalence among all children, with data combined between baseline and follow-up. On the day of the blood draw, survey respondents were asked to recall whether the child had experienced diarrhea as per the World Health Organization case definition (passage of three or more loose or watery stools within 24 hours⁴⁵) within the previous 7 days. The relative risk for diarrheal disease in the previous 7 days in seropositive versus seronegative children was compared for each antigen of interest using repeated measures log binomial models with robust error variance estimation to account for separate measurements taken for each individual child at both baseline and follow-up. To obtain the approximate age of seroconversion against these enteric targets in this population, age-specific MFI-bg values reflecting level of IgG produced were plotted by 3-month age group. All analyses were performed using SAS V9 (SAS Institute, Cary, NC).

Ethical approval. Informed consent was obtained both in writing and verbally. The study protocol and survey instruments were reviewed and approved by the Emory University Institutional Review Board (Ref no. 73615), the London School of Hygiene and Tropical Medicine Research Ethics Committee (Ref no. 7711), the Rwandan National Ethics Committee (Ref no. 1497), and the National Health Research Committee of Rwanda (Ref no. NHRC/2014/PROT/0163). The CRT is registered at Clinicaltrials.gov (NCT02239250).

RESULTS

Samples analyzed. Out of the 251 children who met our age eligibility criteria for enrollment in this seroconversion substudy, 189 children who were 6–12 months old at baseline were ultimately enrolled. A summary of the sample flow and loss is depicted in Figure 1, which is further divided into intervention and control arms in Supplemental Table 1 and 2 for baseline and follow-up. Children were not enrolled if their caregiver did not consent to the blood draw (17%), the child was not at home during the baseline assessment (6%), or if the child was too ill to participate (1%). Of these 189 children, 153 children were available at follow-up; loss to follow-up (19%) was due to refusals (3%), unsuccessful draws (1%),

FIGURE 2. Median immunoglobulin responses, measured by median fluorescence intensity (MFI) to enteric antigens of interest at baseline and follow-up in intervention and control groups.

unavailability of the child (11%), or child illness (5%). Among the 189 children enrolled at baseline, 120 baseline samples, 152 follow-up samples, and 97 paired samples from baseline and follow-up were available for analysis. Samples were deemed insufficient for analysis if spots were less than approximately 90% filled. Descriptive statistics of child and household water and sanitation characteristics at baseline demonstrated reasonable balance between intervention and control groups (Table 1).

Continuous serologic analyses. MFI-bg values for all norovirus antigens, *T. gondii* SAG2A, all *C. parvum* antigens, and *C. jejuni* p18 were successfully log-transformed to fit a normal distribution. Serologic responses against *C. parvum* Cp17 at follow-up were significantly lower in the intervention group than the control group ($t = -2.00$, $P = 0.047$), but the change in log-transformed mean MFI-bg from baseline to follow-up (Δ MFI-bg) did not significantly differ between the two groups. Mean responses in log-transformed MFI values for *C. parvum* Cp23 did not significantly differ between the two intervention arms. There was no statistical difference in serologic response, as measured by median MFI-bg at follow-up and Δ MFI-bg, between intervention and control groups when examining serologic responses against antigens for norovirus or *C. jejuni*. No child appeared to produce any serologic response to *T. gondii* SAG2A throughout the course of the study; therefore, this antigen was dropped from

subsequent analyses. Median responses against *C. jejuni* p39, *G. intestinalis* VSP3 and VSP5, *E. histolytica* LecA, and EtxB and CtxB could not be transformed; therefore, responses to these antigens were only examined using binomial variables derived from threshold cutoffs. Median serologic responses at baseline and follow-up for all antigens are plotted in Figure 2 and displayed in Table 1.

Serologic responses by age. Age-specific median serologic responses to all enteric antigens assessed in this study are displayed in Figure 3. Although children began expressing antibodies to EtxB and CtxB at early ages, the children in our study generally did not begin to produce antibodies against all other antigens until after 12 months of age. *E. histolytica* responses remained markedly low throughout the study period, and responses to *T. gondii* SAG2A were negligible. Antibody responses against Norwalk, Cp17, and Cp23 peaked between 12 and 20 months of age. Serologic responses against *G. intestinalis* VSP3 and VSP5 increased sharply after 12 months of age and remained elevated through 18 months of age (Figure 3).

Impact of intervention on serologic responses. Analyses were performed using both observed (Tables 3 and 4) and imputed data (Supplemental Table 4) to calculate relative risks of both seroprevalence at follow-up and seroconversion between baseline and follow-up for all enteric antigens in this study. Any correlation between baseline and follow-up

measures could indicate the potential for residual expression of antibody spanning both study rounds. To account for any differences in antibody production between the two study arms at baseline, we opted to measure both 1) raw seroprevalence against all antigens at follow-up (Table 3) and 2) seroconversion, measured as seroprevalence at follow-up among children who were seronegative at baseline (Table 4).

Relative risk estimates were comparable for imputed and observed data (Tables 3 and 4 and Supplemental Table 4). Seroprevalence of paired *C. parvum* Cp17 + Cp23 antibodies at follow-up was markedly reduced by 38% among children in the intervention group (adjusted risk ratio [aRR]: 0.62, 95% confidence interval [CI]: 0.44–0.89) (Table 3), although no significant difference was observed in seroconversion (aRR: 0.59, 95% CI: 0.33–1.07) (Table 4). The intervention did not significantly affect seroprevalence or seroconversion of antibody responses against norovirus antigens, *G. intestinalis* VSPs, *E. histolytica* LecA antigen, *C. jejuni* p18 and p39 antigens, or EtxB and CtxB.

Association between seroprevalence against enteropathogens and diarrhea. Seven-day prevalence of diarrheal disease doubled in children with positive serologic responses against both *Giardia* VSP antigens (aRR: 1.94, 95% CI: 1.04–3.63) and among children with seropositivity against both *C. parvum* antigens (aRR: 2.21, 95% CI: 1.09–4.50). Serologic responses against *C. jejuni* p18 and p39, *E. histolytica* LecA, any norovirus VLP, and EtxB and CtxB were not associated with diarrhea prevalence (Table 5).

DISCUSSION

This study demonstrates the potential for the LifeStraw™ Family 2.1 water filter to confer a protective benefit against enteropathogen exposure in children under 2 years of age. Children who resided in households that received the water filter were significantly less likely to be seropositive against *C. parvum* at follow-up than children in the control group. No significant effect was observed for the other enteropathogens explored in this study, indicating that other sources of contamination may be present to counteract some of the protective benefit conferred by the filter. Given recent findings that cases of moderate-to-severe diarrhea attributed to *Cryptosporidium* infection in children 12–23 months old are associated with a higher risk of death,³¹ the water filter's impact on reducing cumulative exposures to this pathogen is in line with priorities to prevent cryptosporidiosis among children in this age group in resource-limited settings.³¹

Examination of age-specific MFI-bg values for each pathogen indicated that the age group targeted by this serologic study was suitable for examination of enteropathogen seroconversion relative to receipt of this water filter intervention. Median MFI values for all pathogens generally did not increase until after 12 months, with the notable exception of EtxB and CtxB, for which median MFI values are elevated even in the first year of life. This comports with the findings of the Global Enteric Multicenter Study (GEMS), which indicated that ETEC was the third leading pathogen associated with moderate-to-severe diarrhea among children 0–11 months old.³¹ Median MFI-bg values for *G. intestinalis* VSP3 and VSP5 antigens remained relatively low throughout the study period, but box

FIGURE 3. Age-specific median immunoglobulin responses by age group among children 6–24 months old against (A) norovirus, (B) bacterial pathogens, such as Enterotoxigenic *Escherichia coli*, *Vibrio cholerae*, and *Campylobacter jejuni*, (C) *Cryptosporidium parvum* antigens, and (D) other protozoa, such as *Giardia intestinalis*, *Entamoeba histolytica*, and *Toxoplasma gondii*.

TABLE 3
Crude and adjusted risk ratios comparing Round 2 seroprevalence among children in the intervention (LFS) and control groups who were 6–12 months old at enrollment

Pathogen	Antigen ¹	Cutoff (MFI-bg)	Method to establish cutoff	Intervention (N = 62) crude seroprevalence	Control (N = 90) crude seroprevalence	Crude RR (95% CI, P value)	Adjusted RR (95% CI, P value)
<i>Giardia intestinalis</i>	VSP3 + VSP5			26 (0.4194)	28 (0.3111)	1.36 (0.91–2.02, 0.135)	1.40 (0.94–2.08, 0.094)
	VSP3	358	Mean + 3SD	26 (0.4194)	30 (0.3333)	1.27 (0.85–1.89, 0.247)	1.30 (0.88–1.93, 0.186)
	VSP5	233	Mean + 3SD	26 (0.4194)	28 (0.3111)	1.36 (0.91–2.02, 0.135)	1.40 (0.94–2.08, 0.094)
<i>Cryptosporidium parvum</i>	Cp17 + Cp23			23 (0.3710)	50 (0.5556)	0.67 (0.46–0.97, 0.035)	0.62 (0.44–0.89, 0.010)
	Cp17	259	ROC	32 (0.5161)	64 (0.7111)	0.73 (0.55–0.96, 0.027)	0.69 (0.52–0.92, 0.010)
	Cp23	662	ROC	30 (0.4839)	53 (0.5889)	0.83 (0.61–1.13, 0.233)	0.78 (0.58–1.04, 0.094)
<i>Campylobacter jejuni</i>	p18 + p39			37 (0.5968)	50 (0.5556)	1.08 (0.81–1.44, 0.594)	1.00 (0.76–1.32, 0.995)
	p18	276	Mixture model	38 (0.6129)	52 (0.5778)	1.07 (0.82–1.40, 0.617)	1.06 (0.81–1.39, 0.653)
	p39	74	Mixture model	45 (0.7258)	63 (0.7000)	1.04 (0.85–1.27, 0.782)	1.00 (0.82–1.23, 0.975)
Norovirus (Norwalk)	VLP	84	Mixture model	28 (0.4242)	39 (0.4105)	0.97 (0.71–1.34, 0.873)	0.84 (0.62–1.14, 0.268)
	VLP	156	Mixture model	21 (0.3387)	44 (0.4889)	0.66 (0.45–0.98, 0.039)	0.63 (0.44–0.90, 0.012)
	VLP	19	Mixture model	26 (0.4267)	45 (0.3947)	1.06 (0.74–1.51, 0.749)	0.94 (0.70–1.27, 0.708)
Norovirus (St. Cloud)		302	Mean + 3SD	6 (0.0968)	7 (0.0778)	1.24 (0.44–3.52, 0.686)	1.42 (0.48–4.15, 0.523)
<i>Entamoeba histolytica</i>	LecA	15474	Mixture model	53 (0.8548)	72 (0.8000)	1.08 (0.91–1.27, 0.392)	1.11 (0.94–1.30, 0.211)
ETEC	CtxB	9882	Mixture model	55 (0.8871)	77 (0.8556)	1.05 (0.91–1.19, 0.519)	1.08 (0.94–1.23, 0.274)
<i>Vibrio cholera</i>	CtxB						

CI = confidence interval; CtxB = cholera toxin β subunit; ETEC = Enterotoxigenic *Escherichia coli*; EtxB = ETEC heat-labile toxin β subunit; LeCA = lectin heavy chain subunit; MFI-bg = median fluorescent intensity values with background subtracted; RR = relative risk; ROC = receiver operating characteristic; SD = standard deviation; VLP = virus-like particle; VSP3 = variant-specific surface protein AS8/GST fusion; VSP5 = variant-specific surface protein 42e/GST fusion. These data incorporate observed values only; samples deemed insufficient at the time of analysis were not included. Log-binomial models were run with robust variance estimation. Significant results (at $\alpha = 0.05$) are highlighted with bold text.

TABLE 4

Crude and adjusted risk ratios comparing Round 2 seroprevalence among children in the intervention (LFS) and control groups who were 6–12 months old and seronegative at enrollment, using observed data only

Pathogen	Antigen ¹	Cutoff (MFI-bg)	Method to establish cutoff	Intervention crude seroprevalence	Control crude seroprevalence	Crude RR (95% CI, P value)	Adjusted RR (95% CI, P value)
<i>Giardia intestinalis</i>	VSP3 + VSP5			11/33 (0.3333)	14/59 (0.2373)	1.45 (0.80–2.69, 0.219)	1.46 (0.79–2.71, 0.228)
	VSP3	358	Mean + 3SD	11/33 (0.3333)	15/59 (0.2542)	1.37 (0.75–2.49, 0.304)	1.37 (0.75–2.52, 0.305)
	VSP5	233	Mean + 3SD	11/33 (0.3333)	14/59 (0.2373)	1.46 (0.79–2.69, 0.219)	1.46 (0.79–2.71, 0.228)
<i>Cryptosporidium parvum</i>	Cp17 + Cp23			9/27 (0.3333)	27/51 (0.5294)	0.64 (0.35–1.15, 0.133)	0.59 (0.33–1.07, 0.082)
	Cp17	259	ROC	15/27 (0.5556)	34/53 (0.6415)	0.88 (0.61–1.26, 0.474)	0.90 (0.61–1.32, 0.577)
	Cp23	662	ROC	14/32 (0.4375)	29/52 (0.5577)	0.83 (0.52–1.32, 0.433)	0.76 (0.48–1.21, 0.252)
<i>Campylobacter jejuni</i>	p18 + p39			12/25 (0.4800)	17/34 (0.5000)	0.99 (0.62–1.56, 0.950)	0.83 (0.52–1.32, 0.425)
	p18	276	Mixture model	15/26 (0.5769)	21/36 (0.5833)	1.06 (0.76–1.50, 0.722)	1.06 (0.81–1.39, 0.653)
	p39	74	Mixture model	16/26 (0.6154)	28/42 (0.6667)	0.85 (0.59–1.22, 0.379)	0.81 (0.56–1.16, 0.253)
Norovirus (Norwalk)	VLP	84	Mixture model	6/32 (0.1875)	20/49 (0.4082)	0.43 (0.18–1.02, 0.055)	0.45 (0.19–1.10, 0.080)
	VLP	156	Mixture model	12/34 (0.3529)	25/56 (0.4464)	0.78 (0.45–1.34, 0.367)	0.77 (0.44–1.34, 0.354)
	VLP	19	Mixture model	16/36 (0.4444)	25/56 (0.4464)	1.15 (0.79–1.66, 0.471)	0.99 (0.72–1.37, 0.955)
Norovirus (St. Cloud)		302	Mean + 3SD	4/33 (0.1212)	5/62 (0.0806)	1.54 (0.43–5.46, 0.507)	1.72 (0.45–6.55, 0.424)
<i>Entamoeba histolytica</i>	LecA	15474	Mixture model	18/24 (0.7500)	31/45 (0.6889)	1.10 (0.81–1.50, 0.537)	1.10 (0.80–1.50, 0.556)
ETEC	CtxB	9882	Mixture model	14/20 (0.7000)	29/38 (0.7632)	0.94 (0.65–1.34, 0.715)	1.07 (0.78–1.46, 0.692)
<i>Vibrio cholera</i>	CtxB						

CI = confidence interval; CtxB = cholera toxin β subunit; ETEC = Enterotoxigenic *Escherichia coli*; EtxB = ETEC heat-labile toxin β subunit; LeCA = lectin heavy chain subunit; MFI-bg = median fluorescent intensity values with background subtracted; RR = relative risk; ROC = receiver operating characteristic; SD = standard deviation; VLP = virus-like particle; VSP3 = variant-specific surface protein AS8/GST fusion; VSP5 = variant-specific surface protein 42e/GST fusion. Log-binomial models account for robust variance estimation. Significant results (at $\alpha = 0.05$) are highlighted with bold text.

TABLE 5
Association between serologic response and 7-day diarrhea prevalence

Pathogen	Antigen	Diarrhea prevalence			
		Serologic response present (%)	Serologic response absent (%)	Unadjusted RR (95% CI, P value)	Adjusted RR (95% CI, P value)
<i>Giardia intestinalis</i>	VSP3 + VSP5	16/59 (0.2712)	34/208 (0.1635)	1.66 (0.97–2.84, 0.065)	1.94 (1.04–3.63, 0.038)
	VSP3	17/61 (0.2787)	34/208 (0.1635)	1.70 (1.01–2.88, 0.046)	1.99 (1.08–3.69, 0.029)
	VSP5	16/59 (0.2712)	35/210 (0.1667)	1.63 (0.95–2.77, 0.074)	1.87 (0.99–3.53, 0.054)
<i>Cryptosporidium parvum</i>	Cp17 + Cp23	19/86 (0.2209)	19/138 (0.1377)	1.60 (0.91–2.84, 0.104)	2.21 (1.09–4.50, 0.029)
	Cp17	29/118 (0.2458)	22/151 (0.1457)	1.69 (1.04–2.74, 0.035)	2.12 (1.21–3.73, 0.009)
	Cp23	22/99 (0.2222)	29/170 (0.1706)	1.30 (0.78–2.16, 0.307)	1.45 (0.82–2.58, 0.205)
<i>Campylobacter jejuni</i>	p18 + p39	24/108 (0.2222)	19/115 (0.1652)	1.35 (0.78–2.33, 0.289)	1.44 (0.76–2.74, 0.267)
	p18	25/118 (0.2119)	26/151 (0.1722)	1.23 (0.76–2.00, 0.401)	1.30 (0.77–2.19, 0.321)
	p39	31/144 (0.2153)	20/125 (0.1600)	1.35 (0.79–2.28, 0.269)	1.40 (0.76–2.57, 0.281)
Norovirus (Norwalk)	VLP	19/92 (0.2065)	32/177 (0.1808)	1.14 (0.95–1.37, 0.625)	1.19 (0.69–2.06, 0.531)
	VLP	14/73 (0.1918)	37/196 (0.1888)	1.02 (0.59–1.75, 0.954)	1.09 (0.59–2.03, 0.779)
	VLP	18/93 (0.1935)	33/176 (0.1875)	1.03 (0.65–1.63, 0.892)	1.08 (0.66–1.77, 0.761)
<i>Entamoeba histolytica</i>	LecA	4/14 (0.2857)	47/255 (0.1843)	1.55 (0.66–3.53, 0.313)	1.48 (0.65–3.38, 0.355)
	EtxB	32/153 (0.2092)	19/116 (0.1638)	1.28 (0.73–2.24, 0.395)	1.71 (0.80–3.66, 0.168)
	CtxB	35/174 (0.2011)	16/95 (0.1684)	1.19 (0.67–2.12, 0.545)	1.48 (0.75–2.89, 0.257)
CI = confidence interval; CtxB = cholera toxin β subunit; ETEC = Enterotoxigenic <i>Escherichia coli</i> ; EtxB = ETEC heat-labile toxin β subunit; LeCA = lectin heavy chain subunit; RR = relative risk; VSP3 = variant-specific surface protein 42e/GST fusion; VSP5 = variant-specific surface protein AS8/GST fusion; VLP = virus-like particle; VSPs = variant-specific surface protein 42e/GST fusion. All adjusted models are adjusted for age and socioeconomic status. Significant results (at $\alpha = 0.05$) are highlighted with bold text.					

*Adjusted for age and socioeconomic status.

plots depicting log-transformed MFI values relative to age group indicated that serologic responses against VSP3 and VSP5 broadly increased after 12 months of age (Figure 4). This indicates that childhood exposure to certain waterborne protozoa, such as *Giardia*, may increase substantially in the immediate postweaning period.

Parametric analyses yielded significantly lower serologic responses against *C. parvum* Cp17 at follow-up, but no statistically significant differences were observed after subtracting responses observed at baseline. Similarly, Cp17 seroprevalence at follow-up, designated as serologic responses falling above the cutoff point, was significantly higher in the control group than the intervention group; however, no statistically significant difference in seroconversion was observed. Since seroconversion analyses rely on a subset of the population who were seronegative at baseline, the study power of the seroconversion analyses could have been compromised.

Serologic responses to *G. intestinalis* and *C. parvum* were associated with diarrheal disease in the previous 7 days, lending further support to the potential utility of serologic assays as an objective method to evaluate the health impact of HWT interventions¹⁶ and to supplement self-reported health outcome data. In addition, the use of culture and PCR-based methods for *Giardia* detection are only useful to identify current and active episodes, and serologic studies may be useful in not only detecting active giardiasis cases but in linking previous *Giardia* infection, determined by serologic evidence, to other long-term health outcomes, such as intestinal enteropathy.⁴⁶ Notably, GEMS found that stool-positive *Cryptosporidium* infection in children aged 12–23 months with moderate-to-severe diarrhea (the same age range as children at follow-up in this study) nearly tripled the risk of death between their enrollment and follow-up periods³¹; this indicates the potential of *C. parvum* seroconversion to be an indicator of early childhood mortality, which is an association that can be explored longitudinally using a larger study population. Since diarrheal disease in children throughout sub-Saharan Africa generally peaks between 6 and 11 months of age,⁴⁷ demonstrated in the baseline analysis of our study,⁴⁸ children are not becoming infected with *Salmonella* during this crucial age window.

IgG antibody responses to ETEC, *Vibrio cholerae*, *C. jejuni*, and norovirus were not associated with diarrheal disease, which is likely due to the relatively short duration of symptomatic illness relative to the 7- to 10-day delay in the development of a primary IgG antibody response. This may indicate a need for longitudinal follow-up in shorter intervals in a similar population of children to record diarrheal disease closer to the time of infection or further from the onset of symptoms, given the short-term acute cases of diarrhea associated with these pathogens and the length of time required to develop an IgG response. Diarrheal disease attributed to protozoa, particularly *Giardia* species, can lead to persistent infection and duodenal inflammation,⁴⁹ which may explain why associations between serologic evidence of previous infection is associated with 1-week prevalence of diarrhea.

There were limitations in the design of this study that may affect the interpretation of these results. It is rare for HWT interventions to be blinded in RCTs for practical purposes, and this lack of blinding can lead to substantial reporting bias in which usage of the intervention and the intervention's

FIGURE 4. Box plots of age-specific prevalence of serologic responses by age group among children 6–24 months old against *Giardia intestinalis* (A) variant-specific surface protein AS8/GST fusion (VSP3) and (B) variant-specific surface protein 42e/GST fusion (VSP5) antigens, represented as log of the median fluorescence intensity with background subtracted.

effect on diarrheal disease are exaggerated.¹¹ Although this seroconversion study seeks to contribute an objective health indicator, it is still being compared with caregiver-reported diarrheal disease, which is subject to bias. Another challenge in assessing water quality interventions is inconsistent intervention uptake.⁵⁰ Among children in intervention households, 23.6% were reported to have consumed some unfiltered water in the previous 24 hours; however, this study used an intention-to-treat analysis to conservatively assess health impact in light of expected imperfect uptake, and water quality characteristics were well balanced between study arms for both the children enrolled in this substudy (Table 1) and in the larger CRT,²⁵ enabling more direct attribution of the intervention effects to the water filter itself.

Statistical- and assay-based limitations in this study involved our limited sample size, imputation methods, and cutoff determination for seropositivity. This serologic study itself was exploratory and nested within a broader CRT, and therefore our study power for this particular nested study was limited by the logistical considerations of the larger CRT. Further complicating this, 36.5% of our baseline blood samples was lost due to quality issues, which we sought to address through multiple imputation methods to account for potential bias attributed to sample loss. In addition, the determination of firm cutoff points for seropositivity is inherently problematic, as some children may be misclassified as seropositive or seronegative on either side of the cutoff point. Cutoff points were assigned in this study using available data for *C. parvum*, *Giardia*, *E. histolytica*, and *T. gondii* antigens, whereas cutoffs points were assigned using mixture models for the antigens of the other enteropathogens examined in this study. Future studies may enable the establishment of firmer cutoff points, but in the meantime, analyses of dichotomized data should be supplemented with continuous analyses to avoid spurious associations. Although primary analyses involved only observed data, data were imputed for the purposes of comparison to correct for bias attributed to missing data in secondary analyses. Multiple imputation assumes that data are missing at random, but children who were lost to follow-up due to illness or caregiver refusals may differ from children who were lost to follow-up for other reasons. That said, caregiver refusals and childhood illnesses were rare at follow-up, and balanced between intervention and control groups when they occurred.

Finally, surveillance data on strain-specific circulation of enteropathogens in this region are limited. Antibody responses to potential circulating strains of *Cryptosporidium* are likely cross-reactive with the *C. parvum* antigens used on our multiplex panel¹⁸ and the region of *Giardia* VSPs used on our panel is highly conserved among human-infecting assemblages; however, little is known about cross-reactivity of *C. jejuni* antigens with other strains of *Campylobacter*. Norovirus strains specific to this region and study period were also not known, so we included all available VLPs from three different norovirus strains (Norwalk, Sydney, and St. Cloud) to account for this limitation. The EtxB and CtxB used for this analysis are homologous proteins, thereby limiting our ability to independently attribute serologic response to either ETEC or *V. cholerae*. Of note, however, EtxB is generally more immunostimulatory than CtxB,⁵¹ which appears to be consistent with results from our study. A systematic way of differentiating between the serologic response to both pathogens is likely not possible; therefore, interpretations at this time should be made with regard to exposure to the toxin itself rather than the causal pathogens.

Although bead-based rotavirus immunoassay methods have not yet been developed, rotavirus is vitally important to consider as a cause of diarrhea in children under 2 years old. Rotavirus-attributable incidence of moderate-to-severe diarrhea among children in this age group far outpaced that of other pathogens in the GEMS study.¹⁵ It should be noted, though, that among children eligible for enrollment in this study at baseline, only 4.1% of children had not initiated their course of rotavirus vaccines, whereas 81.0% of children had received all three doses of rotavirus vaccine, as confirmed by examining the vaccination cards of all children enrolled in the RCT. Rotavirus immunoassay methods used in future WASH trials should be exclusive of the viral glycoproteins targeted by the vaccine.

There is also a possibility of biological interactions between the enteropathogens included in these analyses; infection with one pathogen may either exacerbate or attenuate the risk of infection with another pathogen.⁵² More holistic approaches, such as factor analyses and scoring, may contribute to the body of knowledge of the joint epidemiologic and pathogenic associations between organisms in coinfection scenarios, particularly where opposing effects of the intervention are suggested.

Finally, we cannot make temporal inferences regarding the timing of infection with respect to either diarrheal disease or receipt of the intervention; however, inferences for timing of seroconversion with regard to the intervention are generally better, as households typically received the intervention within a couple of weeks of the initial baseline visit. Longitudinal follow-up with shorter follow-up rounds could have provided the opportunity to capture diarrheal disease closer to the time of infection, which may have provided richer data regarding pathogens that are associated with acute episodes of diarrhea, such as norovirus and *Campylobacter*. Frequent longitudinal collection may also provide a more thorough assessment of age-specific prevalence of individual pathogens.

CONCLUSION

This study suggests that the water filter intervention was effective in reducing seroprevalence of *C. parvum* antibody responses at follow-up. Diarrheal disease within 7 days of sample collection appeared to be associated with IgG antibody responses to protozoan pathogens only. Acute infections caused by other pathogens on the panel may cause diarrhea, but this association may not be detected using serologic antibody detection methods without more frequent sampling intervals. Postponing exposure to these pathogens even for 6 months is important; in our study population, diarrhea prevalence peaked between 12 and 18 months of age⁴⁸ and early childhood diarrhea in general predicts downstream wasting, stunting, and excess mortality.^{6,7,53}

This study also suggests that serologic testing of pathogen-specific antibodies can provide both measures of WASH intervention effectiveness and markers of recent diarrheal disease. Children who are 6–12 months of age at baseline and who can be followed for 6–12 months after intervention deployment comprise the ideal population for WASH seroconversion studies in this region. Longitudinal intervention studies involving larger populations and repeated sampling would provide richer data that would enable further assessment of the utility of these serologic approaches to evaluating WASH interventions.

Received December 20, 2016. Accepted for publication May 29, 2017.

Published online July 24, 2017.

Note: Supplemental Methods and tables appear at www.ajtmh.org.

Financial support: Funding for this research was provided up front by Delagua Inc., the organization that distributed the intervention. The funding was not contingent upon the delivery of results, nor were any authors employed by Delagua.

Disclaimer: Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

Authors' addresses: Laura Divens Zambrano, Department of Environmental Health, Emory University Rollins School of Public Health, Atlanta, GA, E-mail: laura.zambrano@alumni.emory.edu. Jeffrey W. Priest, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: jip8@cdc.gov. Emil Ivan, National Reference Laboratory, Rwanda Biomedical Center, Kigali, RW, E-mail: emil.ivank@gmail.com. John Rusine, Rwanda Biomedical

Center, National Reference Laboratory, Department of Virology, Kigali, RW, E-mail: johnrusine@gmail.com. Corey Nagel, Oregon Health and Science University School of Nursing, Portland, OR, E-mail: nagelc@ohsu.edu. Miles Kirby and Ghislaine Rosa, Department for Disease Control, London School of Hygiene and Tropical Medicine Faculty of Infectious and Tropical Diseases, London, United Kingdom, E-mails: miles.kirby@lshtm.ac.uk and ghislaine.rosa@lshtm.ac.uk. Thomas F. Clasen, Emory University, Rollins School of Public Health, Atlanta, GA, and Department for Disease Control, London School of Hygiene and Tropical Medicine Faculty of Infectious and Tropical Diseases, London, United Kingdom, E-mail: thomas.f.clasen@emory.edu.

REFERENCES

1. Naghavi M, et al., 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 385: 117–171.
2. Vos T, et al., 2015. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 386: 1990–2013.
3. Prüss-Ustün A, et al., 2014. Burden of disease from inadequate water, sanitation and hygiene in low- and middle-income settings: a retrospective analysis of data from 145 countries. *Trop Med Int Health* 19: 894–905.
4. Fischer Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE, 2013. Global burden of childhood pneumonia and diarrhoea. *Lancet* 381: 1405–1416.
5. Weisz A, Meuli G, Thakwalakwa C, Trehan I, Maleta K, Manary M, 2011. The duration of diarrhea and fever is associated with growth faltering in rural Malawian children aged 6–18 months. *Nutr J* 10: 25.
6. Guerrant RL, DeBoer MD, Moore SR, Scharf RJ, Lima AA, 2013. The impoverished gut: a triple burden of diarrhoea, stunting and chronic disease. *Nat Rev Gastroenterol Hepatol* 10: 220–229.
7. Richard SA, et al., 2013. Diarrhea in early childhood: short-term association with weight and long-term association with length. *Am J Epidemiol* 178: 1129–1138.
8. Sinharoy SS, et al., 2016. Child diarrhoea and nutritional status in rural Rwanda: a cross-sectional study to explore contributing environmental and demographic factors. *Trop Med Int Health* 0: 1–9.
9. Clasen T, Alexander K, Sinclair D, Boisson S, Peletz R, Chang H, Majorin F, Cairncross S, 2015. Interventions to improve water quality for preventing diarrhoea. *Cochrane Database Syst Rev* 10: 1–201.
10. Schmidt W-P, Arnold BF, Boisson S, Genser B, Luby SP, Barreto ML, Clasen T, Cairncross S, 2011. Epidemiological methods in diarrhoea studies: an update. *Int J Epidemiol* 40: 1678–1692. Available at: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L363091548>.
11. Clasen T, Boisson S, 2015. Assessing the health impact of water quality interventions in low-income settings: concerns associated with blinded trials and the need for objective outcomes. *Environ Health Perspect* 123: 886–889.
12. Speich B, Croll D, Furst T, Utzinger J, Keiser J, 2016. Effect of sanitation and water treatment on intestinal protozoa infection: a systematic review and meta-analysis. *Lancet* 16: 87–99.
13. Steinberg EB, et al., 2004. Prevalence of infection with water-borne pathogens: a seroepidemiologic study in children 6–36 months old in San Juan Sacatepequez, Guatemala. *Am J Trop Med Hyg* 70: 83–88.
14. Hanson KL, Cartwright CP, 2001. Use of an enzyme immunoassay does not eliminate the need to analyze multiple stool specimens for sensitive detection of *Giardia lamblia*. *J Clin Microbiol* 39: 474–477.
15. Kotloff KL, et al., 2012. The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study. *Clin Infect Dis* 55 (Suppl 4): S232–S245. doi:10.1093/cid/cis753.

16. Crump JA, et al., 2007. Comparing serologic response against enteric pathogens with reported diarrhea to assess the impact of improved household drinking water quality. *Am J Trop Med Hyg* 77: 136–141.
17. Priest JW, Li A, Khan M, Michael J, Lammie PJ, Ong CS, Jacquelin M, Isaac-Newton J, Arrowood MJ, 2001. Enzyme immunoassay detection of antigen-specific immunoglobulin G antibodies in longitudinal serum samples from patients with cryptosporidiosis. *Clin Diagn Lab Immunol* 8: 415–423.
18. Priest JW, et al., 2006. Longitudinal analysis of *Cryptosporidium* species-specific immunoglobulin G antibody responses in Peruvian children. *Clin Vaccine Immunol* 13: 123–131.
19. Moss DM, Priest JW, Boyd A, Weinkopff T, Kucerova Z, Beach MJ, Lammie PJ, 2011. Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis. *Am J Trop Med Hyg* 85: 229–237.
20. Fujii Y, et al., 2014. Serological surveillance development for tropical infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture models. *PLoS Negl Trop Dis* 8: e3040.
21. Lammie PJ, Moss DM, Brook Goodhew E, Hamlin K, Krolewiecki A, West SK, Priest JW, 2012. Development of a new platform for neglected tropical disease surveillance. *Int J Parasitol* 42: 797–800.
22. Moss DM, Priest JW, Hamlin K, Derado G, Herbein J, Petri WA Jr, Lammie PJ, 2014. Longitudinal evaluation of enteric protozoa in Haitian children by stool exam and multiplex serologic assay. *Am J Trop Med Hyg* 90: 653–660.
23. Priest JW, Moss DM, Visvesvara GS, Jones CC, Li A, Isaac-Newton JL, 2010. Multiplex assay detection of immunoglobulin G antibodies that recognize *Giardia intestinalis* and *Cryptosporidium parvum* antigens. *Clin Vaccine Immunol* 17: 1695–1707.
24. Moss DM, Montgomery JM, Newland SV, Priest JW, Lammie PJ, 2004. Detection of cryptosporidium antibodies in sera and oral fluids using multiplex bead assay. *J Parasitol* 90: 397–404.
25. Nagel CL, Kirby MA, Zambrano LD, Rosa G, Barstow CK, Thomas EA, Clasen TF, 2016. Study design of a cluster-randomized controlled trial to evaluate a large-scale distribution of cook stoves and water filters in Western Province, Rwanda. *Contemp Clin Trials Commun* 4: 124–135.
26. Clasen T, Naranjo J, Frauchiger D, Gerba C, 2009. Laboratory assessment of a gravity-fed ultrafiltration water treatment device designed for household use in low-income settings. *Am J Trop Med Hyg* 80: 819–823.
27. Clasen T, Roberts I, Rabie T, Schmidt W, Cairncross S, 2009. Interventions to improve water quality for preventing diarrhoea. *Cochrane Database Syst Rev* 3: CD004794.
28. Barstow CK, Ngabo F, Rosa G, Majorin F, Boisson S, Clasen T, Thomas EA, 2014. Designing and piloting a program to provide water filters and improved cookstoves in Rwanda. *PLoS One* 9: 1–12.
29. Rosa G, Majorin F, Boisson S, Barstow C, Johnson M, Kirby M, Ngabo F, Thomas E, Clasen T, 2014. Assessing the impact of water filters and improved cookstoves on drinking water quality and household air pollution: a randomised controlled trial in Rwanda. *PLoS One* 9: e91011.
30. National Institute of Statistics Rwanda, 2010. *2010 Demographic and Health Survey, Rwanda*. Rockville, MD: The DHS Program.
31. Kotloff KL, et al., 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet* 382: 209–222.
32. Prince JB, Auer KL, Huskinson J, Parmley SF, Araujo FG, Remington JS, 1990. Cloning, expression, and cDNA sequence of surface antigen P22 from *Toxoplasma gondii*. *Mol Biochem Parasitol* 43: 97–106.
33. Morrison HG, et al., 2007. Genomic minimalism in the early diverging intestinal parasite *Giardia lamblia*. *Science* 317: 1921–1926.
34. Bienz M, Siles-Lucas M, Wittwer P, Müller N, 2001. vsp gene expression by *Giardia lamblia* cGS/M-83-H7 during antigenic variation in vivo and in vitro. *Infect Immun* 69: 5278–5285.
35. Schmidt-Ott R, Brass F, Scholz C, Werner C, Gro U, 2005. Improved serodiagnosis of *Campylobacter jejuni* infections using recombinant antigens. *J Med Microbiol* 54: 761–767.
36. Houpt E, Barroso L, Lockhart L, Wright R, Cramer C, Lysterly D, Petri W, 2004. Prevention of intestinal amebiasis by vaccination with the *Entamoeba histolytica* Gal/GalNAc lectin. *Vaccine* 22: 611–617.
37. Priest JW, Moss DM, Arnold BF, Hamlin K, Jones CC, Lammie PJ, 2014. Seroepidemiology of toxoplasma in a coastal region of Haiti: multiplex bead assay detection of immunoglobulin G antibodies that recognize the SAG2A antigen. *Epidemiol Infect* 143: 618–630.
38. Corran PH, et al., 2008. Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. *Malar J* 7: 195.
39. Budcziec J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C, 2012. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. *PLoS One* 7: 1–7.
40. Yuan Y, 2014. *Sensitivity Analysis in Multiple Imputation for Missing Data*. Cary, NC: SAS Institute.
41. Spratt M, Carpenter J, Sterne JAC, Carlin JB, Heron J, Henderson J, Tilling K, 2010. Strategies for multiple imputation in longitudinal studies. *Am J Epidemiol* 172: 478–487.
42. Yuan YC, 2000. *Multiple Imputation for Missing Data Concepts and New Development*, Paper 267–25. SAS SUGI Proc SUGI 25, 1–13. Available at: <http://www2.sas.com/proceedings/sugi25/25/st/25p267.pdf>.
43. Kolenikov S, 2004. *The Use of Discrete Data in PCA: Theory, Simulations, and Applications to Socioeconomic Indices*. Chapel Hill, NC: MEASURE Evaluation.
44. Kolenikov S, Angeles G, 2009. Socioeconomic status measurement with discrete proxy variables: us principal component analysis a reliable answer? *Rev Income Wealth* 55: 128–165.
45. World Health Organization, 2013. *Diarrhoeal Disease*. Geneva, Switzerland: WHO.
46. Platts-Mills JA, McCormick BJJ, Kosek M, Pan WK, Checkley W, Houpt ER; MAL-ED Network Investigators, 2014. Methods of analysis of enteropathogen infection in the MAL-ED cohort study. *Clin Infect Dis* 59 (Suppl 4): S233–S238.
47. Fischer Walker CL, Perin J, Aryee MJ, Boschi-Pinto C, Black RE, 2012. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. *BMC Public Health* 12: 220.
48. Zambrano LD, Kirby M, Rosa G, Nagel C, Clasen TF, 2016. Predictors of diarrhea and coliform contamination of drinking water; a cross-sectional study in Western Province, Rwanda. (submitted).
49. Hanevik K, Hausken T, Morken MH, Strand EA, Mørch K, Coll P, Helgeland L, Langeland N, 2007. Persisting symptoms and duodenal inflammation related to *Giardia duodenalis* infection. *J Infect* 55: 524–530.
50. Boisson S, Stevenson M, Shapiro L, Kumar V, Singh LP, Ward D, Clasen T, 2013. Effect of household-based drinking water chlorination on diarrhoea among children under five in Orissa, India: a double-blind randomised placebo-controlled trial. *PLoS Med* 10: e1001497.
51. Millar DG, Hirst TR, Snider DP, 2001. *Escherichia coli* heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. *Infect Immun* 69: 3476–3482.
52. Cox FE, 2001. Concomitant infections, parasites and immune responses. *Parasitology* 122 (Suppl 1): S23–S38.
53. Fischer Walker CL, Lamberti L, Adair L, Guerrant RL, Lescano AG, Martorell R, Pinkerton RC, Black RE, 2012. Does childhood diarrhea influence cognition beyond the diarrhea-stunting pathway? *PLoS One* 7: 1–6.